Join us for this live webinar to learn about Molecular Classification-based identification of diagnostic and treatment targets in glioma.
Dr. Xiaolong Fan, professor at Beijing Normal University in China will provide a high-level overview of his experience in dealing with the challenges of this project. His team has been pursuing this project for about 15 years and he will describe more about his future research plans.
Key learnings of the webinar
- Despite detailed characterization of genomic alterations, subtype-specific vulnerabilities and treatment options in gliomas are hitherto not identified
- Based on the known developmental pathways converged between brain development and glioma, we developed an EM/PM classification scheme independent of morphological subtypes and grades
- While genetic makeup may change during glioma progression and/or across different tumor areas, developmentally anchored EM/PM subtypes are highly stable and contain subtype-specific vulnerabilities.
Date: Thursday 18th November 2021
Time: 11:00 – 12:00 CET
Venue: Online
Program
| 10:50 | Online platform opens for registering participants |
| 11:00 | Welcome David Munis Zepernick, Head of Business Development and Public Affairs, Medicon Valley Alliance |
| 11:05 | Molecular Classification-based identification of diagnostic and treatment targets in glioma Dr. Xiaolong Fan, Professor at Beijing Normal University |
| 10:50 | Q&A Moderated by Nicholas Gouw Marketing Specialist at GenScript Europe |
| 11:00 | End of webinar |
| Speaker | |
 |
Dr. Xiaolong Fan, Professor at Beijing Normal University
Xiaolong Fan completed doctoral (human genetics) and post-doctoral (bacterial infection biology) training at University Greifswald in Germany between 1989 and 1997, then moved to Lund University, Sweden, worked on hematopoietic stem cell biology and glioma biology, became PI in 2001. Dr. Fan was recruited to Beijing Normal University in 2009. Dr. Fan has since then developed a bioinformatic platform integrating big data analysis with pathways of organ development and cancer pathogenesis, discovered the EM/PM classification scheme for glioma and the MCL1-M classification scheme for multiple myeloma. The seeming heterogeneities are “ordered” into molecular subtypes manifesting subtype-specific aggressiveness and treatment responses driven by distinct pathogenic mechanisms.
|
| Moderator | |
 |
Nicholas Gouw Marketing Specialist at GenScript Europe |
| Organized by | In collaboration with |
 |
 |